CNXU — Q3 FY2026 Financial Report Analysis

A pre-revenue company spent $7.7 million in one quarter, and most of it went to being noticed

Conexeu Sciences is an early-stage regenerative medicine company developing biomaterial-based products for wound care and aesthetics. It has never recorded a dollar of revenue. Its fiscal year ends October 31, so the quarter covered here — the three months ended July 31, 2026 — is the third quarter of fiscal 2026, and it is the first full quarter the company has spent as a public company: the stock began trading on the Nasdaq Capital Market on May 21, 2026 under the symbol CNXU, by way of a direct listing (a listing in which existing shares simply start trading, with no new shares sold and no underwriting bank running a marketing process — so the company raised no money from the listing itself).

The quarter's defining number is not a revenue or margin figure, because there are none. It is that the company reported a net loss of $7,725,651 for three months against $1,298,570 a year earlier, and that only about a sixth of that spending — $270,412 of research and development, plus $235,505 of regulatory fees tied to its planned FDA submission — went into the product it exists to build. The rest went into consulting, business development and management compensation associated with becoming, and staying visible as, a listed stock.

The numbers

Conexeu has no revenue, so the usual margin and profitability ratios have no denominator. In their place, the table below uses two measures that actually describe how a pre-revenue device developer is doing: what it spends on research and development, and what share of total spending that research represents.

All figures are taken directly from the Condensed Interim Statements of Operations in the 10-Q. Per-share losses grew far less than total losses (+222% versus +495%) only because the share count nearly doubled — the denominator grew alongside the loss, which softens the optics without changing the cash consequence.

For the nine months ended July 31, 2026, the net loss was $11,748,757 against $2,046,684 a year earlier, or $(0.52) per share versus $(0.19). Accumulated deficit — the running total of every loss since the company was formed in November 2022 — reached $16,270,277 as of July 31, 2026, up from $4,521,520 at the October 31, 2025 fiscal year-end. In other words, roughly 72% of everything Conexeu has ever lost, it lost in these nine months.

Where the money actually went

The expense lines make the quarter's priorities explicit. Comparing the three months ended July 31, 2026 with the same quarter of 2025:

Consulting alone — $3.78 million in a single quarter — is larger than the company's entire prior-year nine-month loss. Management attributes the increase to non-cash stock compensation "issued to marketing, investor relations, and corporate advisory vendors, valued at then-current Nasdaq trading prices, together with increased engagement of third-party advisors." That valuation mechanic matters: because the shares were priced at the market price on the day they were issued, and the stock traded sharply higher after listing, the accounting charge scales with the share price rather than with the work performed. The company disclosed issuing shares to vendors after quarter-end at $8.89, $7.18 and $7.07 per share — against a $2.30 warrant exercise price used elsewhere in the same filing. A higher stock price mechanically inflates this expense line without any change in the underlying services.

The management compensation increase has a similar character. Three tranches of milestone warrants vested on market events rather than on operational progress: one tranche vested on the Nasdaq listing itself (May 21, 2026) and another on the stock trading at an $80 million market capitalization for 20 consecutive days (achieved June 17, 2026). The grant-date fair values of those tranches — $99,782 and $99,783 for one director, $199,563 and $199,566 for another, among others — were expensed in full and immediately upon achievement, all landing in this one quarter.

The company is candid about why it spent on visibility. Management states that because it listed by direct listing "rather than a traditional underwritten initial public offering, without the marketing support and book-building process typically associated with an underwritten offering, management believed this level of investment was important to establishing market awareness and liquidity in our shares and in supporting our ongoing capital-raising efforts." That is a coherent rationale. It is also an expensive one for a company with no product on the market.

The cash position is the real story

Reported losses at a pre-revenue company are often dominated by non-cash charges, which makes them look worse than the cash reality. Here, that dynamic is present but does not rescue the picture.

Of the nine-month loss, $4,575,266 was non-cash equity compensation ($1,493,977 of options issued for services plus $3,081,289 of shares issued for services, per the cash flow statement), against $893,323 of comparable non-cash equity charges in the prior-year period. Strip that out and Conexeu still consumed $10,099,279 of actual cash in operating activities over nine months, versus $1,238,410 a year earlier.

Cash and cash equivalents fell to $1,971,408 at July 31, 2026 from $4,808,965 at the October 31, 2025 year-end, with a further $238,208 of restricted cash held in trust from exercised warrants. That $2.8 million decline is smaller than the $10.1 million operating outflow only because financing brought in $7,548,009 during the nine months: collection of a $2.0 million private placement subscription that was receivable at year-end, $2,943,351 of net private placement proceeds closed in the first half, and roughly $2.7 million from a Warrant Exercise Incentive Program under which holders exercised warrants and subscribed for new ones at $2.30. Notably, no new private placement closed in the third quarter — financing in the quarter came entirely from warrant inducement exercises, which is a narrower and more opportunistic funding channel than a placement.

One large asset deserves scrutiny. Prepaid expenses — money already paid out for services not yet received — ballooned to $4,544,274 from $549,930 at year-end. Management discloses that roughly $3.7 million of that $4.0 million increase relates to "two business development and marketing service agreements entered into following our Nasdaq listing," one a $3.5 million twelve-month contract running June 2026 through May 2027, the other $0.6 million for services due before October 31, 2026. Prepaid expenses sit on the balance sheet as an asset and are counted in working capital, which the company reports at $5,487,587 — but $4.5 million of that working capital is marketing services already bought and paid for. It cannot be redeployed to fund the lab, the FDA submission or payroll. The company's genuinely liquid resources at quarter-end were the $1.97 million of cash.

Management's own burn arithmetic follows from this. Average monthly operating cash use was approximately $2.3 million during the third quarter, of which roughly $3.3 million in the quarter was prepayment. Excluding one-time listing costs and prepayments, the company estimates a recurring monthly burn of approximately $0.87 million, up from about $0.56 million for the six months ended April 30, 2026. Against $1,971,408 of cash, that recurring rate implies roughly two months of runway at quarter-end. Subsequent to the quarter, on September 4, 2026, four warrant holders exercised 762,608 warrants at $2.30 for gross proceeds of $1,753,998 — useful, but by the company's own assessment "not sufficient, on its own, to resolve the substantial doubt about our ability to continue as a going concern."

That going-concern language is a formal accounting conclusion, not rhetoric: auditors and management must state when there is substantial doubt that a company can meet its obligations for twelve months. Conexeu states it in both Note 2 and the MD&A, and adds that its cash is now expected to last "a substantially shorter period than the 9 to 11 months estimated as of April 30, 2026." The runway estimate was cut sharply in a single quarter, and the spending that cut it was discretionary.

Takeaway: Conexeu spent roughly $6.5 million of the quarter's $7.7 million operating expense on consulting, business development and management compensation, versus $506,000 on R&D and regulatory work combined — and in the same quarter pushed its planned FDA 510(k) submission from June 2026 to March 2027. The company bought market visibility on credit against its own runway, and the delay in the one milestone that would create commercial value is the bill coming due.

What to watch from here

The 510(k) timeline slipped nine months. A 510(k) is the FDA pathway for clearing a medical device by showing it is substantially equivalent to a device already on the market — it is the regulatory gate Conexeu must pass before it can sell anything. As of October 31, 2025 the company anticipated submitting by June 30, 2026. As of July 31, 2026 it anticipates March 31, 2027, and the MD&A's Plan of Operations puts it in "the first quarter of calendar 2027." This is disclosed twice in the warrant-accounting notes as a change in the assumed vesting date for the Milestone 4 warrant tranches, and it is the single most consequential operational fact in the filing. Conexeu states plainly: "We do not expect to generate revenue in the near term."

Financing is now the binding constraint, and it is dilutive by construction. With roughly two months of recurring runway at quarter-end plus $1.75 million from the September warrant exercises, the company needs capital within months, not quarters. Every financing channel it has used — private placements, warrant inducements, shares issued to vendors and directors in lieu of cash — issues stock. Shares outstanding went from 18,906,066 at October 31, 2025 to 27,397,164 at July 31, 2026 to 28,206,698 by September 10, 2026. Existing holders should expect that trajectory to continue. The going-concern disclosure itself notes that equity financing may "cause substantial dilution for our stockholders."

Management has signalled it may cut the marketing spend. The Plan of Operations includes "prudent management of discretionary marketing, investor relations, and business development spending to balance market visibility with capital preservation," and the liquidity section says the company is "evaluating the appropriate ongoing level of such discretionary spending." Whether that materialises in the fourth quarter is the clearest near-term test of whether the third quarter was a deliberate one-time launch investment or a run rate. Note, however, that the $3.5 million marketing contract runs through May 2027 and is already prepaid, so its expense will continue flowing through the income statement regardless of any decision to spend less from here — future quarters will carry amortisation of that prepayment even if no new cash goes out.

Internal controls are not yet fixed. Management concluded that disclosure controls and procedures "were ineffective as of July 31, 2026," and that a previously identified material weakness — specifically "related to the accounting for and disclosure of certain prepaid expenses" — remains under remediation. That the unresolved weakness concerns exactly the line item that grew eightfold this quarter, to become 63% of total assets, is worth flagging. A material weakness means there is a reasonable possibility that a material misstatement would not be prevented or detected in time; it is not itself evidence that the numbers are wrong, but it lowers the confidence an outside reader can place in the one figure that most needs scrutiny.

Own view on trajectory. Nothing in this filing changes the underlying question, which is whether the extracellular matrix platform clears the FDA and finds a market. What the filing does change is the margin for error in getting there. A company that has never earned revenue converted the bulk of a listing-year cash pile into promotional spending, delayed its regulatory submission by three quarters, and now enters fiscal 2027 with under $2 million of unrestricted cash, a disclosed going-concern doubt, an unremediated control weakness over its largest asset, and a need to raise money from a shareholder base it has already diluted by 45% in nine months. The $8.89, $7.18 and $7.07 share prices referenced in the subsequent-events note indicate the market has been receptive so far, which is what makes the next financing possible — but it also means the stock-based portion of the expense base rises with the price, and a decline would pressure the company's ability to pay vendors and directors in shares at all. The next two filings to watch are the FY2026 annual report (fiscal year ending October 31, 2026) for whether the fourth-quarter spend moderated, and any 8-K announcing a financing, for its size and terms.